Meet Genentech and Roche at BIO 2025

PIONEERING PARTNERSHIPS 

Genentech, a member of the Roche Group, pioneered the biotechnology industry and revolutionized treatment for some of the most complex health problems. Our transformational discoveries include the first personalized medicine for cancer and the first medicine for primary progressive multiple sclerosis. Today, we continue to lead the industry — only our quest is bigger and bolder. 

We are galvanizing the greatest minds across our business to make lasting improvements in healthcare. This includes a novel approach to customer engagement focused on local healthcare ecosystems, developing state-of-the-art manufacturing facilities, and integrating AI for molecule discovery.  

Our impact over our nearly 50-year history speaks for itself – but we're just getting started. We aim to continue delivering treatments to improve countless lives for the next 50 years and beyond. 

Together, we can improve all patients' health and quality of life and be a catalyst for driving positive change in society. This requires bringing Genentech and Roche changemakers together alongside trusted partners to achieve a whole that is truly greater than the sum of our parts.